Close Menu

NEW YORK – Molecular diagnostic firm PathoFinder announced Wednesday its SARS-CoV-2 detection kit has obtained the CE mark, allowing it to be marketed in the European Union and other countries recognizing the CE mark. 

The RealAccurate Quadruplex Corona-plus PCR kit detects SARS-CoV-2 from nasopharyngeal and oropharyngeal swabs within two hours. The test also detects Middle East Respiratory Syndrome.

The Maastricht, Netherlands-based company said it expects to be able to deliver "several thousands" of SARS-CoV-2 tests in the coming weeks.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.